Adverse outcomes increased with long-term inhaled corticosteroids in COPD
For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...
Medindia12d
Inhaled Corticosteroids for Lung Disease: Relief Today, Risk Tomorrow
Long-term inhaled corticosteroid (ICS) use for chronic obstructive pulmonary disease/ COPD (lung disease) may increase the ...
Medical Dialogues2d
Long-term inhaled corticosteroid use for COPD linked to serious long-term health risks, suggests research
Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...
GlobalData on MSN12d
EMA to review GSK’s Nucala for COPD treatment expansion
GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...
Monthly Prescribing Reference6d
Adverse Outcomes Increased With Long-Term Inhaled Corticosteroids in COPD
Significantly greater composite adverse outcome rates seen for long- vs short-term inhaled corticosteroid use for prevalent, inception cohorts. HealthDay News — For patients with chronic ...
AOL27d
Are COPD inhalers covered by Medicare?
A person can get a COPD inhaler through Medicare Part D or a ... within a certain period before Medicare starts to fund their treatments. Coinsurance: This is the percentage of treatment costs ...
Pharmabiz11d
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...
Yahoo Finance12d
EMA to review GSK’s Nucala for COPD treatment expansion
Despite its established use in other conditions, the antibody is not yet approved for COPD treatment in any nation ... antibody as an add-on therapy to inhaled triple therapy in individuals ...